Atea Pharmaceuticals (AVIR) Stock Forecast: StockMap's 2-Week Call

AVIR stock forecast: StockMap's model leans Underperform on Atea Pharmaceuticals for the two weeks after the Nov 13 close, toward AVIR trailing the growth index. It is a lean inside the no-call band, not a call, and not a price target. Right in 3 of 3 two-week windows on AVIR since Sep 24; by chance, a call on the same dates was right 51% of the time.

Atea Pharmaceuticals last closed at $4.30, +2.14% on the session.

Against the IVW growth benchmark the position is +3.05% over the forecast window.

Atea Pharmaceuticals' market cap is $345.31M as of November 13, 2026.

Leans down ↘: a small lean, not a call · the next 2 weeks, vs S&P 500 growth. The lean on a scale from −100 to +100 is -42 (too close to call).

Where AVIR sits: sized by market cap, coloured by the day's move.

The read is built from 15 underlying insights — 1 bullish and 14 bearish.

Agreement across those insights is 93%.

23 daily calls for AVIR so far. We publish our accuracy across thousands of stocks in the open, misses included — no per-stock hit rate is claimed on a small sample.

On the fundamentals StockMap ranks Atea Pharmaceuticals in the 15th percentile on return on equity, where 100 is best.

Atea Pharmaceuticals is classified under Health Care / Pharmaceuticals.

StockMap tracks Atea Pharmaceuticals as the 83rd largest of the 152 companies it covers in the Pharmaceuticals industry, part of the Health Care sector.

Across that group the current two-week reads are 73 Moderate Underperform, 49 Neutral and 30 Strong Underperform.

On that composite Atea Pharmaceuticals ranks 104th of 152 in the group, against a group median of -0.33.

Other Health Care stocks

Research and education, not investment advice. The calls on this page come from StockMap's automated model, run on the close of November 13, 2026, and are the same for every reader. Calls are graded in public, misses included: how calls are graded, and the record. Who makes the calls and who pays for the site: Disclosures.

Atea Pharmaceuticals (AVIR) — StockMap 2-week forecast & tracked accuracy